Hamlet BioPharma Enters Commercial Collaborations with Top International Advisory Firms to Enhance Partnering and Strategic Alliances
Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, is proud to announce that it has entered into commercial collaborations with two premier international advisory firms. Under the new collaborations, the advisory firms will offer expert support to Hamlet BioPharma, leveraging their global networks and deep industry knowledge to identify and negotiate potential partnerships for commercial opportunities and strategic alliances.
“The collaborations are expected to accelerate Hamlet BioPharma’s strategic partnering initiatives and enhance its global reach in the pharmaceutical sector”, says Martin Erixon, CEO of Hamlet BioPharma.
“These agreements mark a significant milestone in Hamlet BioPharma’s commitment to creating value for the company´s drug development assets”, says Catharina Svanborg, founder and chairman of the board of Hamlet BioPharma.
The advisory firms have specialist expertise within the biopharma healthcare sector globally and have acted as advisors on numerous deals related projects for companies worldwide. With deal analytics and networks of contacts from innovators to large pharma they are uniquely placed to support deal making and strategic planning.
For further information, please contact:
Catharina Svanborg, Chairman and Founder of Hamlet BioPharma, +46-709 42 65 49
Martin Erixon, CEO Hamlet BioPharma, +46-733 00 43 77
